KAINOS Laboratories

4556

The current KAINOS Laboratories (4556) market capitalization is approximately ¥5.65B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, KAINOS Laboratories's market cap fluctuates with changes in its share price and share count. Last updated: January 1, 2026 at 12:11 AM Eastern Time

In the most recently reported quarter, KAINOS Laboratories (4556) generated ¥1.38B in revenue, representing a +6.06% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 3:59 AM Eastern Time

In the most recently reported fiscal year, KAINOS Laboratories (4556) generated net income of ¥641.00M, compared with ¥637.00M in the prior fiscal year, representing a +0.63% year over year change. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 3:59 AM Eastern Time

In the most recently reported quarter, KAINOS Laboratories (4556) revenue was ¥1.38B. Earnings per share (EPS) for the quarter were ¥33.73. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 3:59 AM Eastern Time

KAINOS Laboratories (4556) does not currently pay a dividend. Over the last twelve months (LTM), the company paid ¥0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: January 1, 2026 at 3:59 AM Eastern Time

Based on the latest available analyst coverage, KAINOS Laboratories (4556) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 3:59 AM Eastern Time

Like other publicly traded stocks, KAINOS Laboratories (4556) shares are bought and sold on stock exchanges such as TSE and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for KAINOS Laboratories (4556) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add 4556 to your watchlist.

KAINOS Laboratories trades under the ticker symbol 4556 on the TSE stock exchange. The ticker 4556 is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, KAINOS Laboratories (4556) employs approximately 133 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: January 1, 2026 at 12:11 AM Eastern Time

KAINOS Laboratories (4556) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest KAINOS Laboratories (4556) stock peers based on overlapping products, services, and competitive dynamics:Rockwell Medical (RMTI)Guerbet (GBT)Paul Hartmann (PHH2)ICU Medical (ICUI)Convatec Group (CTEC) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to KAINOS Laboratories.